Large institutional experience with dose-intensive chemotherapy and stem cell support in the management of sarcoma patients

Oncology

Volumn 73, Issue 1-2, 2008, Pages 58-64

  Kasper, Bernd ^a   Dietrich, Sascha ^a   Mechtersheimer, Gunhild ^a   Ho, Anthony D ^a   Egerer, Gerlinde ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Bone sarcomas; High dose chemotherapy; Soft tissue sarcomas; Stem cell support

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; MESNA; SAMARIUM 153;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE SEVERITY; DRUG MEGADOSE; EXPERIENCE; FEMALE; HEALTH CENTER; HEART ARREST; HUMAN; HUMAN TISSUE; MALE; MONOTHERAPY; OSTEOSARCOMA; PRIORITY JOURNAL; REMISSION; STEM CELL TRANSPLANTATION; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHONDROSARCOMA; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEIOMYOSARCOMA; LIPOSARCOMA; MALE; MIDDLE AGED; OSTEOSARCOMA; RETROSPECTIVE STUDIES; RHABDOMYOSARCOMA; SARCOMA; SARCOMA, EWING'S; SARCOMA, SYNOVIAL; STEM CELL TRANSPLANTATION;

EID: 41549150415     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000120629     Document Type: Article

References (39)

1. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, Mouridsen H, Crowther D, Somers R, Verweij J, Santoro A, Buesa J, Tursz T: Prognostic factors in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens - a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. J Clin Oncol 1999;17:150-157.
2. Edmonson JH, Ryan LM, Blum RG, Brooks JS, Shiraki M, Frytak S, Parkinson DR: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993;11:1269-1275.
3. Antman KH, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, Elias A, Natale RB, Cooper RM, Barlogie B, Trump DL, et al: An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993;11:1276-1285.
4. Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, Bueas J, Casali P, Spooner D, Rankin E, et al: Doxorubicin versus CyVADic versus ifosfamide plus doxorubicin in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995;13:1537-1545.
5. Bui NB, Demaille MC, Chevreau C, Blay JY, Cupissol D, Rios M, Thyss A, Maugard C, Bastit P, Bay JO, Tanguy A, Fargeot P, Lortholary A, Bonichon F: qMAID vs. MAID + 25% in adults with advanced soft tissue sarcoma (STS): first results of a randomized study of the FNCLCC Sarcoma Group (abstract 1991). Proc Am Soc Clin Oncol 1998;17:517a.
6. Blay JY, van Glabbeke M, Nielsen OS, van Oosterom AT, Tursz T, Oosterhuis JW, Verweij J: Five-year survivors in patients (pts) with advanced soft tissue sarcoma (ASTS) treated with doxorubicin: a study on 1742 patients (STBSG) (abstract 19973). Proc Am Soc Clin Oncol 1998;17:512a
7. Standard-Options-Recommendations, vol 1: Sarcome des Tissus Mous et Ostéosarcomes. Paris, Arnette Blackwell, 1995, pp 1-113.
8. Demetri GD, Elias AD: Results of singleagent and combination chemotherapy for advanced soft tissue sarcomas: implications for decision making in the clinic. Hematol Oncol Clin North Am 1995;9:765-785.
9. Verweij J, Mouridsen HT, Nielsen OS, Woll PJ, Somers R, van Oosterom AT, Van Glabbeke M, Tursz T: The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view. Crit Rev Oncol Hematol 1995;20:193-201.
10. Rosen G, Forscher C, Lowenbraun S, Eilber F, Eckardt J, Holmes C, Fu YS: Synovial sarcoma: uniform response of metastases to high dose ifosfamide. Cancer 1994;73:2506-2511.
11. Patel SR, Vadhan-Raj S, Papadopolous N, Plager C, Burgess MA, Hays C, Benjamin RS: High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies - dose-response and schedule dependence. J Clin Oncol 1997;15:2378-2384.
12. Le Cesne A, Antoine E, Spielmann M, Le Chevalier T, Brain E, Toussaint C, Janin N, Kayitalire L, Fontaine F, Genin J, et al: High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995;13:1600-1608.
13. Saeter G, Alvegard TA, Monge OR, Strander H, Turesson I, Klepp R, Soderberg M, Wist E, Raabe N, Erlanson M, Solheim OP, Hannisdal E: Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma: a Scandinavian Sarcoma Group phase II study. Eur J Cancer 1997;33:1551-1558.
14. Jelic S, Kovcin V, Milanovic N, Babovic N, Kreacic M, Ristovic Z, Vlajic M, Filipovic-Ljeskovic I: Randomised study of high-dose epirubicin versus high-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcoma. Eur J Cancer 1997;33:220-225.
15. Reichardt P, Tilgner J, Hohenberger P, Dorken B: Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study. J Clin Oncol 1998;16:1438-1443.
16. Bokemeyer C, Franzke A, Hartmann JT, Schober C, Arseniev L, Metzner B, Link H, Kanz L, Schmoll HJ: A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer 1997;80:1221-1227.
17. Elias AD, Ayash LJ, Wheeler C, Schwartz G, Tepler I, Gonin R, McCauley M, Mazanet R, Schnipper L, Frei R 3rd, et al: Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support. Bone Marrow Transplant 1995;15:373-379.
18. Dumontet C, Biron P, Bouffet E, Blay JY, Meckenstock R, Chauvin F, Philip I, Clavel M, Brunat-Mentigny M, Philip T: High dose chemotherapy with ABMT in soft tissue sarcomas: a report of 22 cases. Bone Marrow Transplant 1992;10:405-408.
19. Mesia R, Sola C, Lopez Pousa A, Mendoza L, Bellet M, Andres L, Lopez Lopez JJ: High-dose chemotherapy and autologous bone marrow transplantation in high-grade metastatic sarcomas. Rev Clin Esp 1994;194:960-965.
20. Wiklund T, Saeter G, Strander H, Alvegard T, Blomqvist C: The outcome of advanced soft tissue sarcoma patients with complete tumour regression after either chemotherapy alone or chemotherapy plus surgery: the Scandinavian Sarcoma Group experience. Eur J Cancer 1997;33:357-361.
21. Seynaeve C, Verweij J: High-dose chemotherapy in adult sarcomas: no standard yet. Semin Oncol 1999;26:119-133.
22. Horowitz ME, Kinsella TJ, Wexler LH: Total-body irradiation and autologous bone marrow transplant in the treatment of highrisk Ewing's sarcoma and rhabdomyosarcoma. J Clin Oncol 1993;11:1911-1918.
23. Burdach S, Jurgens H, Peters C, Nurnberger W, Mauz-Korholz C, Korholz D, Paulussen M, Papa H, Dilloo D, Koscielniak E, et al: Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J Clin Oncol 1993;11:1482-1488.
24. Boulad F, Kernan NA, LaQuaglia MP, Heller G, Lindsley KL, Rosenfield NS, Abramson SJ, Gerald WL, Small TN, Gillio AP, Gulati SC, O'Reilly RJ, Ghavimi F: High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing's sarcoma, and undifferentiated sarcoma. J Clin Oncol 1998;16:1697-1706.
25. Fagioli F, Aglietta M, Tienghi A, Ferrari S, Brach del Prever A, Vassallo E, Palmero A, Biasin E, Bacci G, Picci P, Madon E: Highdose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study. J Clin Oncol 2002;20:2150-2156.
26. Sauerbrey A, Bielack S, Kempf-Bielack B, Zoubek A, Paulussen M, Zintl F: High-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (ASCT) as salvage therapy for relapsed osteosarcoma. Bone Marrow Transplant 2001;27:933-937.
27. Meyers PA: High-dose therapy with autologous stem cell rescue for pediatric sarcomas. Curr Opin Oncol 2004;16:120-125.
28. Kalambakas SA, Moore TB, Feig SA: Megatherapy and stem cell transplantation for Ewing's family of tumors: a critical review of current literature. Pediatr Transplant 2004;8(suppl 5):83-88.
29. Elias AD: High-dose therapy for adult soft tissue sarcoma: dose response and survival. Semin Oncol 1998;25:19-23, 45-48.
30. Reichardt P: High-dose chemotherapy in adult soft tissue sarcoma. Crit Rev Oncol Hematol 2002;41:157-167.
31. Blay JY, Bouhour D, Ray-Coquard I, Dumontet C, Philip T, Biron P: High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults. J Clin Oncol 2000;18:3643-3650.
32. Ray-Coquard I, Biron P, Blay JY: High-dose chemotherapy in soft tissue sarcomas of adults. Bull Cancer 2001;88:858-862.
33. Rosti G, Ferrante P, Ledermann J, Leyvraz S, Ladenstein R, Koscileniak E, Crown J, Dazzi C, Cariello A, Marangolo M: High-dose chemotherapy for solid tumors: results of the EBMT. Crit Rev Oncol Hematol 2002;41:129-140.
34. Schlemmer M, Wendtner CM, Falk M, Abdel-Rahmen S, Licht T, Baumert J, Straka C, Hentrich M, Salat C, Hiddemann W, Issels RD: Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas. Oncology 2006;71:32-39.
35. Reichardt P, Verweij J, Crowther D: Current controversies in cancer: should high-dose chemotherapy be used in the treatment of soft-tissue sarcoma? Eur J Cancer 1997;33:1351-1360.
36. Kasper B, Lehnert T, Bernd L, Mechtersheimer G, Goldschmidt H, Ho AD, Egerer G: High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas. Bone Marrow Transplant 2004;34:37-41.
37. Kasper B, Ho AD, Egerer G: Is there an indication for high-dose chemotherapy in the treatment of bone and soft-tissue sarcoma? Oncology 2005;68:115-121.
38. Verweij J: Etoposide for soft tissue sarcomas: fact or fiction. Eur J Cancer 1997;33:1527-1528.
39. Ferrari S, Alvegard T, Luksch R, Tienghi A, Hall KS, Bernini G, Brach del Prever A, Picci P, Bacci G, Smeland S: Non-metastatic Ewing's family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients: preliminary results of the Italian/Scandinavian ISG/SSG III protocol (abstract 10014). Proc Am Soc Clin Oncol 2007;25:S18.